Market News & Trends
Exavir Therapeutics Announces Preclinical Data Demonstrating Complete Elimination of HIV From Human Cells With LNP-Delivered Tat-Targeted CRISPR-Cas9
Exavir Therapeutics recently announced the publication of preclinical data for XVIR-TAT, Exavir’s proprietary gene editing program in early preclinical development as a potential cure for…
Finch Therapeutics Announces Positive Topline Data From Phase 2 PRISM-EXT Open-Label Study of Microbiome Therapy for Recurrent C. diff.
Finch Therapeutics Group, Inc. recently announced positive topline results from PRISM-EXT, an open-label extension of the company’s PRISM3 Phase 2 placebo-controlled trial evaluating CP101 for…
Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients With Parkinson’s Disease
Yumanity Therapeutics recently reported its lead product candidate, YTX-7739, in development for the treatment of Parkinson’s disease, achieved its primary endpoints in a randomized, placebo-controlled…
CN Bio & iiCON Announce COVID-19 Research Collaboration
CN Bio recently announced a research collaboration with the Infection Innovation Consortium (iiCON), a global collaborative infectious disease R&D program, to validate the next-generation of…
Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan
Rain Therapeutics Inc. recently announced its plan to commence a Phase 2 clinical trial, named MANTRA-3, evaluating the efficacy of milademetan, an oral mouse double…
Synlogic & Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria
Synlogic, Inc. and Ginkgo Bioworks recently announced the nomination of SYNB1353, an investigational Synthetic Biotic medicine for the treatment of homocystinuria (HCU). SYNB1353 is the…
Eton Pharmaceuticals & Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA Oral Solution
Eton Pharmaceuticals, Inc and Azurity Pharmaceuticals, Inc. recently announced the US FDA has approved EPRONTIA (topiramate) oral solution, 25 mg/mL. EPRONTIA has been approved as…
Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity Against Human Common Coronaviruses, Noroviruses, Rhinoviruses & Enteroviruses
Cocrystal Pharma, Inc. recently announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respiratory enteroviruses…
TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients
TFF Pharmaceuticals, Inc. recently announced the completion of dosing in the Phase 1b clinical trial of Voriconazole Inhalation Powder (TFF VORI), a next-generation, direct-to-lung, inhaled…
PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate & Breast Cancers From National Cancer Institute
PDS Biotechnology Corporation recently announced a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI’s proprietary tumor-associated and immunologically active…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….